2024 ESMO Congress Preview for Medical Oncologists: The Show and After Show

As the fall conference season kicks off, the European Society of Medical Oncology (ESMO) Congress 2024 has captivated a variety of medical oncologists’ attention across social media channels, with data from the presidential symposiums being top of mind.

In the next episode of The Show and After Show, co-hosts Kristie L. Kahl and Andrew Svonavec offer a glimpse at some of the presentations guaranteed to spark one’s curiosity, spur debate, and enhance the field even further. Some key highlights include:

Genitourinary Cancer

• NIAGARA (NCT03732677) trial: Thomas Powles, MBBS, MRCP, MD, professor of genitourinary oncology, director, Barts Cancer Centre at St. Bartholomew's Hospital, will present results from the phase 3 NIAGARA trial, designed to evaluate neoadjuvant durvalumab (Imfinzi) plus chemotherapy in patients with muscle-invasive bladder cancer.

Breast Cancer

• KEYNOTE-522 (NCT03036488) study: Peter Schmid, FRCP, MD, PhD, professor of cancer medicine; centre lead, Centre of Experimental Cancer Medicine; director, Barts Breast Cancer Centre, will present overall survival results from the phase 3 KEYNOTE-522 study evaluating neoadjuvant pembrolizumab (Keytruda) or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo in patients with high-risk early-stage triple-negative breast cancer.

The co-hosts touch on even more presentations coming out of ESMO Congress 2024, including more data from the genitourinary space, a promising study in cervical cancer, as well as emerging technologies as the use of AI grows in popularity.

ESMO Congress 2024 isn't just about data, as the duo also offers food recommendations, tourist attractions and fun activities to partake in, as well as interesting facts about Barcelona.

This is just a taste of the wealth of information and inspiration waiting at ESMO Congress 2024. Check back for future meeting previews with The Show and After Show.